


## Anti-Human CD261 (DR4) PE

**Catalog Number:** 12-6644

**Also Known As:** TRAIL Receptor 1, TRAIL-R1, TRAILR1

**RUO: For Research Use Only. Not for use in diagnostic procedures.**



Staining of human CD261-transfected cells with Anti-Human CD261 (DR4) Biotin followed by Streptavidin PE (cat. 12-4317). Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.

### Product Information

**Contents:** Anti-Human CD261 (DR4) PE

**REF** **Catalog Number:** 12-6644

**Clone:** DJR1

**Concentration:** 5 µL (0.5 µg)/test

**Host/Isotype:** Mouse IgG1, kappa

**Formulation:** aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer



**Temperature Limitation:** Store at 2-8°C. Do not freeze. Light sensitive material.



**Batch Code:** Refer to Vial



**Use By:** Refer to Vial



**Caution, contains Azide**

### Description

The DJR1 monoclonal antibody reacts with human DR4, also known as TRAIL-R1. DR4 binds to TRAIL, activates NF-κB, and induces TRAIL-mediated apoptosis. DR4 is expressed by a variety of human tumor cells and at very low level on human leukocytes.

Expression has also been found inside the cell on some cell lines (Zhang *et al*). This has been confirmed with intracellular staining of Jurkat cell line. Please contact tech@ebioscience.com for more information.

### Applications Reported

The DJR1 antibody has been reported for use in flow cytometric analysis.

### Applications Tested

This DJR1 antibody has been pre-titrated and tested by flow cytometric analysis of human DR4-transfected cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10<sup>5</sup> to 10<sup>8</sup> cells/test.

### References

Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. *Hepatology*. 2006 Feb;43(2):362-72. (**DJR1**, IHC frozen, PubMed)

Earel JK Jr, Vanoosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. *Cancer Res*. 2006 Jan 1;66(1):499-507. (**DJR1**, FC)

Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. *Cancer Res*. 1999 Jun 1;59(11):2747-53.

### Related Products

12-4317 Streptavidin PE

12-4714 Mouse IgG1 K Isotype Control PE (P3.6.2.1)

Not for further distribution without written consent.

Copyright © 2000-2010 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • [www.eBioscience.com](http://www.eBioscience.com) • [info@eBioscience.com](mailto:info@eBioscience.com)